Newsbenzinga
Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…